Evolution of costs of cancer drugs in a Portuguese hospital

Table 1 Drugs selected in the study and their date of introduction to the Portuguese market

Drugs on the national market before 1999	Market placement yr	Drugs on the national market before 1999	Market placement yr	Drugs on the national market between 1999 and 2010	Market placement yr
Aldesleukin	1992	Ifosfamide	1979	Bleomycin	2001
Amifostine	1995	Interferon Alfa-2A	1998	Capecitabine	2001
Anastrozole	1996	Intravenous vinorelbine	1993	Exemestane	1999
Bicalutamide	1998	Irinotecan	1997	Hydroxyurea	2001
Bleomycin	1998	Letrozole	1997	Imatinib	2001
Carboplatin	1989	Megestrol	1987	Ketoconazole	2002
Carmustine	1983	Melphalan	1966	Leuprorelin	1999
Chlorambucil	1966	Mercaptopurine	1997	Liposomal Doxorubicin	2000
Cisplatin	1980	Methotrexate	1993	Oral vinorelbine	2001
Cyclophosphamide	1960	Mitomycin	1984	Raltitrexed	2001
Cyclosporine	1990	Mitoxantrone	1998	Temozolomide	1999
Cyproterone	1994	Octreotide	1989	Trastuzumab	2000
Cytarabine	1996	Oxaliplatin	1993	Anagrelide	2004
Dacarbazine	2000	Paclitaxel	1997	Bevacizumab	2005
Dactinomycin	1980	Pegylated liposomal doxorubicin	1996	Bortezomib	2004
Docetaxel	1995	Procarbazine	1998	Cetuximab	2004
Doxorubicin	1998	Rituximab	1998	Erlotinib	2005
Epirubicin	1992	Tamoxifen	1984	Fulvestrant	2004
Etoposide	1998	Tegafur	1985	Interleukin 2	2005
Estramustine	1982	Thalidomide	1961	Pemetrexed	2004
Fludarabine	1995	Topotecan	1996	Azacitidine	2008
Fluorouracil	1997	Vaccine, Bacillus Calmette-Guerin	1992	Lapatinib	2008
Flutamide	1998	Vinblastine	1991	Sorafenib	2006
Gemcitabine	1996	Vincristine	1993	Sunitinib	2006
Goserelin	1998			Temsirolimus	2007
Idarubicin	1995			Trabectedin	2008